share_log

Palisade Bio Analyst Ratings

Benzinga Analyst Ratings ·  Aug 19, 2022 08:20
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/19/2022 Maxim Group Downgrades Buy → Hold
02/02/2022 2946.92% Ladenburg Thalmann → $5 Initiates Coverage On → Buy
08/31/2021 4165.69% Maxim Group → $7 Initiates Coverage On → Buy

Palisade Bio Questions & Answers

What is the target price for Palisade Bio (PALI)?

The latest price target for Palisade Bio (NASDAQ: PALI) was reported by Maxim Group on August 19, 2022. The analyst firm set a price target for $0.00 expecting PALI to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Palisade Bio (PALI)?

The latest analyst rating for Palisade Bio (NASDAQ: PALI) was provided by Maxim Group, and Palisade Bio downgraded their hold rating.

When is the next analyst rating going to be posted or updated for Palisade Bio (PALI)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Palisade Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Palisade Bio was filed on August 19, 2022 so you should expect the next rating to be made available sometime around August 19, 2023.

Is the Analyst Rating Palisade Bio (PALI) correct?

While ratings are subjective and will change, the latest Palisade Bio (PALI) rating was a downgraded with a price target of $0.00 to $0.00. The current price Palisade Bio (PALI) is trading at is $0.16, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment